Colette Brooks
Nurse Practitioner · Virginia Beach, VANPI 1083362396
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 427 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $3,930 and has fallen 94.6% since, to $211 in 2025. Among nurse practitioner clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 427 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Abbott$760
- Amgen$717
- Cequr Corporation$703
- Insulet Corporation$690
- Corcept Therapeutics$642
- plus $4K from 27 others
What the payments were for
- Food & beverage$9,287100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 79 | $1,305 |
| Abbott | 42 | $760 |
| Amgen | 31 | $717 |
| Cequr Corporation | 4 | $703 |
| Insulet Corporation | 26 | $690 |
| Corcept Therapeutics | 23 | $642 |
| Sanofi-aventis U.S. LLC | 23 | $537 |
| Lilly USA, LLC | 27 | $530 |
| Bayer | 23 | $488 |
| Xeris Pharmaceuticals, Inc. | 16 | $433 |
| Radius Health, Inc. | 18 | $348 |
| AbbVie | 25 | $255 |
| Novartis | 14 | $250 |
| Amneal Pharmaceuticals LLC | 13 | $241 |
| IBSA Pharma Inc. | 5 | $214 |
| AstraZeneca(2 entities) | 6 | $175 |
| Medtronic | 6 | $168 |
| Dexcom, Inc. | 5 | $136 |
| Boehringer Ingelheim | 8 | $126 |
| Merck | 8 | $125 |
| Pfizer | 4 | $85 |
| Antares Pharma, Inc. | 3 | $59 |
| Recordati_rare_diseases_inc. | 3 | $52 |
| BD | 2 | $43 |
| Tolmar, Inc. | 3 | $41 |
| Tandem Diabetes Care, Inc. | 2 | $38 |
| Embecta Corp. | 1 | $32 |
| Amarin Pharma, Inc. | 2 | $30 |
| Lifescan, Inc. | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| BETA Bionics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$652
- GVOKE HYPOPEN$129
- Tirosint$125
- Omnipod$106
- EVENITY$102
How this compares
$9,310 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 263 | $553,759 |
| JardianceEmpagliflozin | 171 | $253,662 |
| TrulicityDulaglutide | 108 | $184,622 |
| JanuviaSitagliptin Phosphate | 92 | $112,905 |
| FarxigaDapagliflozin Propanediol | 75 | $93,993 |
| RybelsusSemaglutide | 34 | $73,214 |
| MounjaroTirzepatide | 48 | $53,655 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $53,560 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 30 | $45,543 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $41,928 |
| TradjentaLinagliptin | 34 | $40,071 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $36,177 |
| Novolog FlexpenInsulin Aspart | 72 | $27,160 |
| GlyxambiEmpagliflozin/Linagliptin | 23 | $26,467 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 53 | $26,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,305 | $626,973297 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $126 | $320,200228 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $530 | $238,277156 claims |
| MerckJanuvia | $125 | $112,90592 claims |
| AstraZenecaFarxiga | $175 | $93,99375 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $241 | $6,551536 claims |
| AbbVieSynthroid | $255 | $5,40180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Other nurse practitioner in Virginia Beach
- Kristin AustriaVirginia Beach$26K
- Kimberly ClovisVirginia Beach$14K
- Lisa WalkerVirginia Beach$11K
- Barbara McCrayVirginia Beach$10K
- Matthew GilbertVirginia Beach$10K
- Samantha FoxGate City$207K
- Mikel GrayCharlottesville$174K
- Kevin BrigleRichmond$166K
- Denese GomesRichmond$126K
- Ashley CarmenAlexandria$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.